Gilead's Harvoni beats Sovaldi, AbbVie's Viekira Pak in hep C drug safety: Advera

Drug safety numbers have been weighing in Gilead's ($GILD) favor lately, with recent analyses showing that its hep C superstars Harvoni and Sovaldi are safer than AbbVie's ($ABBV) rival med Viekira Pak. But Harvoni could be the safest option of the three, turning up the fewest reports of serious side effects, according to a new report by healthcare informatics firm Advera Health Analytics. More from FiercePharma

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.

AbbVie and Allergan's merger may create the fourth-largest drugmaker in the world, but it could also create opportunities for other drugmakers.